CD19 and neoplasm: A range of bi-specific antibodies (BSABs) are being tested under clinical trials, for instance Blinatumomab (targeting CD19 tumour-associated antigen and CD3 on immune effector cells) in a phase 1/2 trial which revealed significant tumour remission in patients with refractory or relapsed B-cell acute lymphoblastic leukaemia (79).